Maingon P, Horiot J C, Fraisse J, Salas S, Collin F, Bône-Lepinoy M C, Barillot I, Douvier S, Padéano M M, Cuisenier J
Centre Georges-François-Leclerc, Dijon, France.
Radiother Oncol. 1996 Jun;39(3):201-8. doi: 10.1016/0167-8140(96)01743-4.
From 1972 to 1993, 170 patients received preoperative radiotherapy followed, 5-6 weeks later, by total extrafascial hysterectomy with bilateral salpingo-oophorectomy without lymphadenectomy. Eighty-three patients with good prognostic factors (low grade tumour and no cervical involvement) received low dose rate utero vaginal brachytherapy alone before surgery (Group 1). Eighty-seven patients with poor prognostic factors (high grade tumors and/or cervical involvement) received external radiotherapy to 40 Gy and low dose rate brachytherapy before surgery (Group 2). A single vaginal failure was observed (0.6%). The overall pelvic failure rate was 2.3% (four patients) including two cases with pelvic recurrence and metastases. Three of the four pelvic failures occurred in Group 1. Using the 1971 FIGO clinical staging, 5-year disease-free survival was 82% in Stage Ia, 79% in Stage Ib, and 81% in Stage II (P = 0.36). Five-year disease-free survival was 86% in Grade 1, 76% in Grade 2, and 83% in Grade 3 (P = 0.20). Five-year overall survival was 83% in Stage Ia, 79% in Stage Ib, and 83% in Stage II (P = 0.78). Five-year overall survival was 88% in Grade 1, 77% in Grade 2,83% in Grade 3 (P = 0.27). Complications were recorded with the French-Italian syllabus. Grade 2 complications occurred in 12 cases (7%), Grade 3 in five cases (3%). The lack of correlation between classical risk factors (stage, grade) and disease outcome suggests that preoperative radiotherapy strategies should be preferred when such factors can be identified before surgery.
1972年至1993年期间,170例患者接受了术前放疗,5至6周后进行了全筋膜外子宫切除术及双侧输卵管卵巢切除术,未行淋巴结清扫术。83例具有良好预后因素(低级别肿瘤且无宫颈受累)的患者在手术前仅接受了低剂量率子宫阴道近距离放疗(第1组)。87例具有不良预后因素(高级别肿瘤和/或宫颈受累)的患者在手术前接受了40 Gy的外照射放疗和低剂量率近距离放疗(第2组)。观察到1例阴道复发(0.6%)。总体盆腔复发率为2.3%(4例患者),包括2例盆腔复发和转移病例。4例盆腔复发中有3例发生在第1组。根据1971年国际妇产科联盟(FIGO)临床分期,Ia期5年无病生存率为82%,Ib期为79%,II期为81%(P = 0.36)。1级5年无病生存率为86%,2级为76%,3级为83%(P = 0.20)。Ia期5年总生存率为83%,Ib期为79%,II期为83%(P = 0.78)。1级5年总生存率为88%,2级为77%,3级为83%(P = 0.27)。并发症按照法国-意大利标准进行记录。2级并发症发生12例(7%),3级并发症发生5例(3%)。经典危险因素(分期、分级)与疾病转归之间缺乏相关性,这表明当术前能够识别这些因素时,术前放疗策略更值得推荐。